β-Adrenergic blockers: A 50-year historical perspective

American Journal of Therapeutics

Volumn 15, Issue 6, 2008, Pages 565-576

  Frishman, William H ^a  

^a WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

Adrenergic receptors; Catecholamine blockade; G protein receptors; History of adrenergic blockers; adrenergic blockade; adrenergic blockade

Indexed keywords

ACEBUTOLOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; BUCINDOLOL; CARTEOLOL; CARVEDILOL; DEXPROPRANOLOL; DICHLORISOPRENALINE; ESMOLOL; GUANINE NUCLEOTIDE BINDING PROTEIN; HORMONE; ISOPRENALINE; LABETALOL; METOPROLOL; NADOLOL; NEBIVOLOL; NEUROTRANSMITTER; PENBUTOLOL; PINDOLOL; PROPRANOLOL; SOTALOL; TIMOLOL; UNINDEXED DRUG;

BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOVASCULAR DISEASE; DRUG INDICATION; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; HISTORY; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPOGLYCEMIA; METABOLIC DISORDER; MOLECULAR PROBE; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; WEIGHT GAIN;

EID: 57649131068     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Frishman WH. Alpha- and beta-adrenergic blocking drugs. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Pharmacotherapeutics. 2nd ed. New York: McGraw Hill; 2003:67-97.
2. Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol. 1948;153:586-599.
3. Lefkowitz RJ. Seven transmembrane receptors: something old, something new. Acta Physiol. 2007;190:9-19.
4. Lefkowitz RJ. A magnificent time with the "magnificent seven" transmembrane spanning receptors. Circ Res. 2003;92:342-344.
5. Frielle T, Daniel KW, Caron MG, et al. Structural basis of β-adrenergic receptor subtype specificity studied with chimeric β1/β2-adrenergic receptors. Proc Natl Acad Sci U S A. 1988;85:9494-9498.
6. Dixon RA, Kobilka BK, Strader DJ, et al. Cloning of the gene and cDNA for mammalian β-adrenergic receptor and homology with rhodopsin. Nature. 1986;321:75-79.
7. 2 adrenergic G-protein-coupled receptor. Nature. 2007;450:383-388.
8. Lefkowitz RJ. The superfamily of heptahelical receptors. Nat Cell Biol. 2000;2:E133-E136.
9. Lefkowitz RJ, Rajagopal K, Whalen EJ. New roles for β-arrestins in cell signaling: not just for seven-transmembrane receptors. Mol Cell. 2006;24:643-652.
10. Powell CE, Slater IH. Blocking of inhibitory adrenergic receptors by a dichloro analogue of isoproterenol. J Pharmacol Exp Ther. 1958;122:480-488.
11. Black JW, Crowther AF, Shanks RG, et al. A new adrenergic beta receptor antagonist. Lancet. 1964;1:1080-1081.
12. Frishman WH. β-Adrenoceptor antagonists. New drugs and new indications. N Engl J Med. 1981;305:505-506.
13. Lands AM, Arnold A, McAuliff JP, et al. Differentiation of receptor systems activated by sympathomimetic amine. Nature. 1967;214:597-598.
14. Koch-Weser J. Drug therapy: metoprolol. N Engl J Med. 1979;301:698-703.
15. Wright P. Untoward effect associated with practolol administration: oculomucocutaneous syndrome. Br Med J. 1975;1:595-598.
16. nd ed. New York: McGraw Hill;2005:19-57.
17. Frishman WH. Pindolol: a new β adrenoceptor antagonist with partial agonist activity. N Engl J Med. 1983;308:940-944.
18. Frishman WH. Clinical differences between beta-adrenergic blocking agents: implications for therapeutic substitution. Am Heart J. 1987;113:1190-1198.
19. Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet. 1990;336:1-6.
20. Frishman W, Halprin S. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part VII: new horizons in beta-adrenoceptor blocking therapy: labetalol. Am Heart J. 1979;98:660-665.
21. Frishman WH, Sica DA. β-Adrenergic blockers. In: Izzo JL Jr, Sica D, Black HR, eds. Hypertension Primer. The Essentials of High Blood Pressure. 4th ed. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Willems; 2008: 446-450.
22. Frishman WH. Carvedilol. NEngl J Med. 1998;339:1759-1765.
23. Wisler JW, DeWire SM, Whalen EJ, et al. A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling. Proc Natl Acad Sci U S A. 2007;104:16657-16662.
24. Sule SS, Frishman W. Nebivolol. New therapy update. Cardiol Rev. 2006;14:259-264.
25. Frishman WH, Lazar EJ, Gorodokin G. Pharmacokinetic optimization of therapy with beta- adrenergic blocking agents. Clin Pharmacokinet. 1991;20:311-318.
26. Frishman WH. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1: pharmacokinetic and pharmacodynamic properties. Am Heart J. 1979;97:663-670.
27. Toprol XL [package insert]. Wilmington, DE: AstraZeneca; 2006.
28. Coreg CR (Carvedilol phosphate) extended release capsules [package insert]. Research Triangle Park, NC: GlaxoSmithKlein; 2007.
29. Frishman WH. Atenolol and timolol, two new systemic adrenoceptor antagonists. N Engl J Med. 1982;306:1456-1462.
30. Frishman WH. Nadolol: a new β-adrenoceptor antagonist. N Engl J Med. 1981;305:678-684.
31. Frishman WH, Furberg CD, Friedewald WT. β-adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med. 1984;310:830-837.
32. Murthy VS, Frishman WH. Controlled beta receptor blockade with esmolol and flestolol. Pharmacotherapy. 1988;8:168-182.
33. Sung RJ, Blanski L, Kirschenbaum J, et al. Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia. J Clin Pharmacol. 1986;26 (Suppl A):A15-A26.
34. Ward SA, Walle T, Walle UK, et al. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther. 1989;45:72-79.
35. COSOPT (dorzolamide/timolol package insert). White-house Station, NJ: Merck & Co.; 2003.
36. Hamer J, Grandjean T, Melendez L, et al. Effect of propranolol (Inderal) in angina pectoris: preliminary report. Br Med J. 1964;2:720-723.
37. Frishman WH. Multifactorial actions of beta-adrenergic blocking drugs in ischemic heart disease. Circulation. 1983;67(Suppl 1):I11-I18.
38. Inderide (propranolol hydrochloride and hydrochlorothiazide) tablet [package insert]. Madison, NJ: Wyeth Pharmaceuticals; 2006.
39. Atenolol [package insert]. Corona, CA: Watson Pharmaceuticals; 2006.
40. Corzide (nadolol and bendroflumethiazide) tablet [package insert]. Bristol, TN: Monarch Pharmaceuticals; 2006.
41. Frishman WH, Cavusoglu E. β-adrenergic blockers and their role in the therapy of arrhythmias. In: Podrid PJ, Kowey PR, eds. Cardiac Arrhythmias: Mechanisms, Diagnosis and Management. Baltimore, MD: Williams & Wilkins; 1995:421-433.
42. Esmolol [package insert]. Bedford, OH: Ben Venue Laboratories; 2004.
43. Sotalol [package insert]. Montville, NJ: Berlex Laboratories; 2004.
44. Cavusoglu E, Frishman WH. Sotalol: a new β-adrenergic blocker for ventricular arrhythmias. Prog Cardiovasc Dis. 1995;37:423-440.
45. Prichard BNC. Hypotensive action of pronethalol. Br Med J. 1964;1:1227-1228.
46. Prichard BNC, Gillam PMS. Use of propranolol (Inderal) in the treatment of hypertension. Br Med J. 1964;2:725-727.
47. Chobanian AV, Bakris GL, Black HR, et al and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC 7 report. JAMA. 2003;289:2560-2572.
48. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:1684-1689.
49. Cutler JA, Davis BR. Should β blockers and diuretics remain as first-line therapy for hypertension? Circulation. 2008;117:2691-2705.
50. Sarafidis P, Bogojevic Z, Basta E, et al. Comparative efficacy of two different β blockers on 24-hour blood pressure control. J Clin Hypertens. 2008;10:112-118.
51. Ram CVS. β blockers in hypertension: truths and half-truths (editorial). J Clin Hypertens. 2008;10:516-519.
52. Weber MA, Bakris GL, Giles TD, et al. β blockers in the treatment of hypertension: new data, new directions. J Clin Hypertens. 2008;10:234-238.
53. Chrysant SG, Chrysant GS, Dimas B. Current and future status of beta blockers in the treatment of hypertension. Clin Cardiol. 2008;31:249-252.
54. Bakris GL, Fonseca V, Katholi RE, et al for the GEMINI Investigators. Metabolic effects of Carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227-2236.
55. Braunwald E. Treatment of the patient after myocardial infarction. N Engl J Med. 1980;302:290-293.
56. MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomized placebo-controlled international trial. Eur Heart J. 1985;6:199-226.
57. Lopressor Intervention Trial Research Group. The Lopressor Intervention Trial: multicenter study of metoprolol in survivors of acute myocardial infarction. Eur Heart J. 1987;8:1056-1064.
58. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet. 2001;357:1385-1390.
59. Engelmeier RS, O'Connell JB, Walsh R, et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation. 1985;72:536-546.
60. LeJemtel TH, Sonnenblick EH, Frishman WH. Diagnosis and management of heart failure. In: Fuster V, Alexander RW, O'Rourke RA, et al, eds. Hurst's The Heart. 11th ed. New York: McGraw Hill; 2004:723-762.
61. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215-225.
62. Beta Blocker Evaluation of Survival Trial Investigators. A trial of the beta blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-1667.
63. Cohen LS, Braunwald E. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation. 1967;35:847-851.
64. Winkle RA, Lopes MG, Goodman DS, et al. Propranolol for patients with mitral valve prolapse. Am Heart J. 1970;93:422-427.
65. Dorostkar PC, Eldar M, Belhassen B, et al. Long-term follow up of patients with long QT syndrome treated with β blockers and continuous pacing. Circulation. 1999;100:2431-2436.
66. Kornbluth A, Frishman WH, Ackerman B. Beta-adrenergic blockade in children. Cardiol Clin. 1987;5:629-649.
67. Slater EE, DeSanctis RW. Dissection of the aorta. Med Clin North Am. 1979;63:141-154.
68. Rios AS, Silber EN, Bavishi N, et al. Effect of long-term β blockade on aortic root compliance in patients with Marfan syndrome. Am Heart J. 1999;137:1057-1061.
69. Frishman WH, Razin A, Swencionis C, et al. Beta-adrenoceptor blockade in anxiety states: a new approach to therapy. Update. Cardiovasc Rev Rep (Classics of the Decade Series). 1992;13:8-13.
70. Harte B, Jaffer AK. Perioperative beta-blockers in non-cardiac surgery: evolution of the evidence. Cleve Clin J Med. 2008;75:513-519.
71. Mangano DT, Layug EL, Wallace A, et al. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter study of perioperative ischemia research group. N Engl J Med. 1996;335:1713-1720.
72. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med. 1999;341:1789-1794.
73. Shojania KG, Duncan BW, McDonald KM, et al. Making health care safer: a critical analysis of patient safety practices. Evid Rep Technol Assess (Summ). 2003;43:1-668.
74. National Quality Forum. Safe Practices for Better Health-care - 2006 Update. Washington, DC: National quality Forum; 2006.
75. POISE Study Group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE Trial): a randomized controlled trial. Lancet. 2008;371:1839-1847.
76. Fleisher LA, Poldermans D. Perioperative β blockade: where do we go from here? (comment). Lancet. 2008;371:1813-1814.
77. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. Executive summary: a report of the ACC/AHA Task Force on Practice Guidelines. Circulation. 2007;116:1971-1996.
78. Weber RB, Reimuth OM. The treatment of migraine with propranolol. Neurology. 1972;22:366-369.
79. Young RR, Growdon JH, Shahani BT. Beta-adrenergic mechanisms in action tremor. N Engl J Med. 1975;293:950-953.
80. Han JA, Frishman WH, Sun SW, et al. Cardiovascular and respiratory considerations with pharmacotherapy of glaucoma and ocular hypertension. Cardiol Rev. 2008;16:95-108.
81. Kraus ML, Gottlieb LD, Horwitz RI, et al. Randomized clinical trial of atenolol in patients with alcohol withdrawal. N Engl J Med. 1985;313:905-909.
82. Gluud LL, Klingenberg S, Nikolova D, et al. Banding ligation versus beta blockers as primary prophylaxis in esophageal varices: systematic review of randomized trials. Am J Gastroenterol. 2007;102:2842-2848.
83. Frishman WH, Clark A, Johnson B. Effects of cardiovascular drugs on plasma lipids and lipoproteins. In: Frishman WH, Sonnenblick EH, eds. Cardiovascular Pharmacotherapeutics. New York: McGraw Hill; 1997: 1515-1559.
84. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201-207.
85. Frishman WH. Beta-adrenergic blocker withdrawal. Am J Cardiol. 1987;59:26F-32F.
86. Fonarow GC, Abraham WT, Albert NM, et al, on behalf of the OPTIMIZE-HF Investigators and Coordinators. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure. J Am Coll Cardiol. 2008;52:190-199.